Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

Novo Nordisk (NVO), which develops weight-loss ... Congress to increase the amount of time that drugs can be sold to Medicare without the government negotiating the prices to 13 years from nine ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...